Dermatology News

The European Commission has extended approval for Celltrion Healthcare’s subcutaneous infliximab biosimilar to treat adults with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.

A previously healthy 15-year-old female presents for a virtual clinic visit for bilateral foot pain for the last 2 days. The pain began in her toes, then progressed to painful, erythematous nodules on her soles.

Understanding the myriad cutaneous manifestations of conditions like systemic lupus erythematosus will aid rheumatologists in providing better care for their patients, according to a presenter at the 2020 Interdisciplinary Autoimmune Summit.

Rapid development of personal technologies may lead to improved outcomes but additional challenges for the clinical and research communities dealing with conditions like inflammatory arthritis, according to a presenter at the 2020 Interdisciplinary Autoimmune Summit.

Clinicians who manage patients with immune-mediated diseases can offer useful insight into the management of COVID-19, according to presenters at a roundtable discussion at the 2020 Interdisciplinary Autoimmune Summit.

Synovitis, acne, pustulosis, hyperostosis, osteomyelitis — collectively known as SAPHO syndrome — in pustular psoriasis remains for most rheumatologists a rare enigma with an unclear pathogenesis, according to Philip Helliwell, PhD, DM, BM BCh, FRCP, MA, of the University of Leeds.

While FDA- and EU-approved JAK inhibitors have shown comparable efficacy and safety across a spectrum of immune-mediated diseases, more study is required to fully parse the mechanism of action, according to a presenter at the 2020 Interdisciplinary Autoimmune Summit.

In the face of the unique threat that COVID-19 poses to patients with autoimmune diseases, communication across disciplines is essential “as our fields increasingly blend together,” noted presenters at the 2020 Interdisciplinary Autoimmune Summit.

The FDA has approved the sixth biosimilar to adalimumab, adalimumab-fkjp, for all eligible indications of the biologic product, according to a company press release.

A previously healthy, unvaccinated 17-year-old male presents with a progressive illness that began on a Monday with fatigue and loss of appetite.